AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2025
Mar 8, 2025
32883_dirs_2025-03-07_48a38613-7708-43df-b3a5-7eae06d503be.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-03-04
Reporting Person: Cittadine Andrew (Chief Operating Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-04 | Stock Options | $31.70 | A | 43445 | Acquired | 2035-03-04 | Common Stock (43445) | Direct |
| 2025-03-04 | Restricted Stock Units | $0 | A | 40581 | Acquired | Common Stock (40581) | Direct |
Footnotes
F1: Options Vests 6/48ths on June 30, 2025, and 1/48th per month thereafter.
F2: RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.